This combination therapy is considered relevant for four key therapeutic areas. The primary use is to provide reliable oral contraception to prevent pregnancy. Furthermore, it is commonly used to help with managing symptoms that interfere with daily functioning such as the severe mood and physical distress of Premenstrual Dysphoric Disorder (PMDD), addressing symptoms of moderate acne vulgaris, and providing precautionary nutritional support.

The medication supports the establishment of more predictable menstrual cycles, which may assist with reducing the pain (dysmenorrhea) and heaviness (menorrhagia) of periods. This focus on symptoms related to systemic imbalance may assist with maintaining functional stability and helps improve day-to-day comfort.

“The formulation is applied across domains where additional symptomatic support is needed, which supports the patient during difficult episodes by easing distress.”

It is used for managing specific, recurrent symptom clusters, including the severe emotional symptoms of PMDD, physical discomfort from fluid retention and bloating, and the skin manifestations of moderate acne.

Quick Fact: Supportive Management for Cyclical Discomfort
Symptom Domain: Supports management of severe, cyclical mood changes and physical symptoms like bloating.
Primary Benefit: May assist with maintaining functional stability during phases of heightened premenstrual distress.

Eligibility for Yasmin Plus

Yasmin Plus is indicated for use by females of reproductive potential after they have achieved menarche (their first menstrual period). The product is not indicated for use after menopause.

Eligibility Status	Key Populations/Conditions
Contraindicated	Presence or history of arterial or venous thrombotic diseases (e.g., deep vein thrombosis, pulmonary embolism, stroke, myocardial infarction), or a known hereditary predisposition for clotting disorders.
Contraindicated	Severe or uncontrolled medical conditions, including uncontrolled hypertension, diabetes with vascular involvement, severe renal insufficiency or acute renal failure, adrenal insufficiency, and severe hepatic disease or liver tumors.
Contraindicated	Known or suspected pregnancy, or known or suspected sex-hormone dependent malignancies (e.g., breast cancer).
Not Recommended	Women who smoke and are over 35 years old. Nursing mothers (can decrease milk production). Women who have recently had a baby (must wait at least four weeks postpartum).

Regulatory documents explicitly prohibit use in the presence of these contraindications due to significantly increased health risks, especially related to thromboembolic events.

This section outlines the officially documented interaction patterns for Yasmin Plus (Drospirenone, Ethinylestradiol, and Levomefolate Calcium), as specified in government regulatory sources. All listed interactions are based on label text and not clinical advice or mechanism extrapolation.

Official Contraindicated Combinations

Co-administration with the following drug classes or specific agents is strictly prohibited by regulatory authorities:

Classification	Interacting Agents	Rationale in Regulatory Labeling
Hepatitis C Therapy	Ombitasvir, Paritaprevir/Ritonavir, with or without Dasabuvir	High potential for significant elevation of liver enzymes (ALT increases).
Potassium-Sparing Diuretics	Amiloride, Spironolactone	Increased risk of hyperkalemia due to Drospirenone's anti-mineralocorticoid activity.

Documented Exposure-Modifying Interactions

Substances that significantly alter the plasma concentrations of the hormonal components are identified in official labeling:

• CYP3A4 Inducers: Strong or moderate enzyme inducers such as Apalutamide, Armodafinil, and Bosentan are documented to decrease the levels or effects of Ethinylestradiol and/or Drospirenone via CYP3A4 metabolism.
• Other Agents: Medications like Atazanavir and Belzutifan are noted to cause significant changes (decrease or increase) in estrogen plasma levels or decrease the product’s effect.

Pharmacodynamic and Population Constraints

Interactions relating to physiological effects and specific patient groups are officially documented:

• Hyperkalemia Risk: Agents known to increase serum potassium levels (e.g., ACE inhibitors, certain NSAIDs) have an additive effect with Drospirenone's activity. Women on long-term treatment with these agents are required to have their serum potassium concentration monitored during the first treatment cycle.
• Food Interactions: Consumption of grapefruit or grapefruit juice is documented to potentially increase the level of estrogens in the body, which may alter the pharmacokinetics of Ethinylestradiol.

The pharmacodynamic action of Yasmin Plus is mediated by the synthetic hormones, drospirenone (a progestin) and ethinyl estradiol (an estrogen). The primary system-level modulation is the suppression of pituitary gonadotropins, specifically Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH), via negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis. This results in the inhibition of follicular maturation and the absence of the LH surge, thus preventing ovulation.

Drospirenone acts as a high-affinity agonist at the progesterone receptor. It also functions as a competitive antagonist at the mineralocorticoid receptor and the androgen receptor. The combined hormonal effects also induce cellular changes in the female reproductive tract, including increased cervical mucus viscosity and altered endometrial receptivity. Levomefolate calcium, the active form of folate, is included to raise systemic folate levels through its absorption and distribution.

The administration of Yasmin Plus is structured as a fixed-dose, 28-day cyclic regimen taken orally. The medication is provided as film-coated tablets in a blister pack that includes 24 hormone-containing tablets, followed by 4 hormone-free tablets containing only folate. The entire course is administered as one tablet once daily.

Dosing Schedule and Timing

To ensure proper use, the tablet must be taken at the same time every day, consistently following the specific sequential order printed on the calendar pack. The tablet can be taken with or without regard to meals, though it is often suggested to take it after the evening meal or at bedtime.

When initiating therapy, procedures permit starting either on Day 1 (the first day of the menstrual period) or using a Sunday Start (the first Sunday after the period begins). If the patient starts later than Day 1, a non-hormonal back-up method is required for the initial seven consecutive days of active tablet use. Following the 28-day course, a new pack must be started immediately to maintain continuous cyclic administration.

Population Use

The product is indicated for the treatment of moderate acne vulgaris only in women who have achieved menarche and are at least 14 years of age.

Research Evidence / Overview of Studies for Yasmin Plus

---

1. Evidence for Use in Preventing Pregnancy (Contraception)

Research for pregnancy prevention was primarily established through pivotal clinical trials. These studies monitor individuals using the medication over a set period, often one year, to measure pregnancy incidence. The primary measure used in this research was the Pearl Index, which describes what patterns of pregnancy incidence were observed in large groups using a contraceptive method. Because the hormonal components of Yasmin Plus are established in a widely studied formulation, its bioequivalence to that formulation was evaluated in dedicated studies. While use in large populations was observed in these trials, the data for long-term use often rely on observational settings evaluating daily-life functioning and post-marketing surveillance reports. There is limited information for long-term outcomes following immediate cessation of use.

---

2. Evidence for Improvement in Folate Status

Research was conducted using randomized controlled trials (RCTs) to specifically explore the non-hormonal, folate component. The outcomes monitored were observed in relation to physiological changes, such as nutritional biomarkers, specifically Red Blood Cell (RBC) folate levels and plasma folate levels. Data show patterns related to RBC and plasma folate concentrations being measured as higher in individuals who participated in studies using the formulation that included the folate supplement. The role of sufficient folate intake is a public health principle, but the direct clinical outcome for this specific product is based on biomarker endpoints. What remains uncertain is whether the increase in folate levels leads to a specific clinical outcome for the user.

---

3. Evidence for Use in Managing Premenstrual Dysphoric Disorder (PMDD) and Moderate Acne

The research for Premenstrual Dysphoric Disorder (PMDD) relied on short-term, randomized, double-blind, placebo-controlled trials. These studies focused on outcomes related to systemic or functional imbalance using standardized tools, like the Daily Record of Severity of Problems (DRSP) score. Studies report how symptoms evolved in the observed populations over the short study period, typically three menstrual cycles. Evidence is limited for outcomes beyond these three cycles.

For Moderate Acne Vulgaris, the evidence was evaluated in controlled clinical trials, often lasting six months. Studies primarily focused on outcomes linked to inflammatory or irritative states by monitoring changes in lesion counts. The research examined the hormonal combination for acne, without the folate component being a focus. Limited information for long-term outcomes exists, as follow-up durations were typically restricted to the six-month period of the main trials.

Key Studies & References U.S. National Institutes of Health (NIH) - Folate

Common questions about Yasmin Plus (FAQ)

---

Q: What should I do if I miss a Yasmin Plus pill?

Official drug labeling confirms that specific steps should be taken if a hormone-containing tablet is missed. The necessary action, such as taking a tablet late, using a back-up method, or starting a new pack, depends on the week of your cycle and the number of pills missed. The full protocol for managing a missed tablet is detailed in the official patient information leaflet.

---

Q: Does Yasmin Plus interact with antibiotics?

Regulatory documents state that certain medicines that affect liver enzymes, including some antibiotics like rifampicin, are documented to decrease the blood levels and overall effectiveness of the hormonal components. This may reduce the pill’s efficacy. Official product information contains detailed warnings for known interacting agents.

---

Q: What is the benefit of the folate in the pill?

The non-hormonal component, Levomefolate Calcium (a form of folate), is included to support an increase in the user's folate levels. According to official information, this public health measure is intended to help reduce the risk of certain serious birth defects, such as neural tube defects, should a woman become pregnant shortly after stopping the medication.

---

Q: What is the difference between Yasmin and Yasmin Plus?

The primary distinction is the composition. Yasmin contains only the two active hormones, Drospirenone and Ethinyl Estradiol. Yasmin Plus contains these two hormones plus a third, non-hormonal active ingredient, Levomefolate Calcium (folate), which is included for nutritional support.

---

Q: When does the Drospirenone anti-mineralocorticoid activity become a concern?

The anti-mineralocorticoid activity of drospirenone is associated with the risk of hyperkalemia (high serum potassium levels). Official prescribing information prohibits its use in patients with certain conditions that predispose them to this risk, such as kidney or adrenal insufficiency. Monitoring of serum potassium may be necessary for patients also taking other potassium-increasing agents.

How to Store and Dispose of Yasmin Plus

Official regulatory documents define specific conditions necessary to maintain the quality and stability of Yasmin Plus (Drospirenone, Ethinyl Estradiol, and Levomefolate Calcium).

---

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, typically 25 C (77 F).
Protection	Keep the tablets in the original container to protect them from moisture and light.
Handling	Avoid storing the medication above 30 C (86 F).
Child Safety	Keep out of the sight and reach of children.

---

Disposal Instructions

Expired or unused Yasmin Plus must be disposed of according to established procedures for pharmaceutical waste. Regulatory guidance mandates that the medication must not be disposed of in household waste or flushed down wastewater to prevent environmental contamination. The product should be discarded using a drug take-back program or following local requirements for disposing of unused pharmaceuticals.